Cargando…

Pediatric Microdose Study of [(14)C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept

BACKGROUND: Pediatric drug development is hampered by practical, ethical, and scientific challenges. Microdosing is a promising new method to obtain pharmacokinetic data in children with minimal burden and minimal risk. The use of a labeled oral microdose offers the added benefit to study intestinal...

Descripción completa

Detalles Bibliográficos
Autores principales: Mooij, Miriam G., van Duijn, Esther, Knibbe, Catherijne A. J., Windhorst, Albert D., Hendrikse, N. Harry, Vaes, Wouter H. J., Spaans, Edwin, Fabriek, Babs O., Sandman, Hugo, Grossouw, Dimitri, Hanff, Lidwien M., Janssen, Paul J. J. M., Koch, Birgit C. P., Tibboel, Dick, de Wildt, Saskia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213380/
https://www.ncbi.nlm.nih.gov/pubmed/25227283
http://dx.doi.org/10.1007/s40262-014-0176-8
Descripción
Sumario:BACKGROUND: Pediatric drug development is hampered by practical, ethical, and scientific challenges. Microdosing is a promising new method to obtain pharmacokinetic data in children with minimal burden and minimal risk. The use of a labeled oral microdose offers the added benefit to study intestinal and hepatic drug disposition in children already receiving an intravenous therapeutic drug dose for clinical reasons. OBJECTIVE: The objective of this study was to present pilot data of an oral [(14)C]paracetamol [acetaminophen (AAP)] microdosing study as proof of concept to study developmental pharmacokinetics in children. METHODS: In an open-label microdose pharmacokinetic pilot study, infants (0–6 years of age) received a single oral [(14)C]AAP microdose (3.3 ng/kg, 60 Bq/kg) in addition to intravenous therapeutic doses of AAP (15 mg/kg intravenous every 6 h). Blood samples were taken from an indwelling catheter. AAP blood concentrations were measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS) and [(14)C]AAP and metabolites ([(14)C]AAP-Glu and [(14)C]AAP-4Sul) were measured by accelerator mass spectrometry. RESULTS: Ten infants (aged 0.1–83.1 months) were included; one was excluded as he vomited shortly after administration. In nine patients, [(14)C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (C (max)) [(14)C]AAP 1.68 (0.75–4.76) ng/L, [(14)C]AAP-Glu 0.88 (0.34–1.55) ng/L, and [(14)C]AAP-4Sul 0.81 (0.29–2.10) ng/L. Dose-normalized oral [(14)C]AAP C (max) approached median intravenous average concentrations (C (av)): 8.41 mg/L (3.75–23.78 mg/L) and 8.87 mg/L (3.45–12.9 mg/L), respectively. CONCLUSIONS: We demonstrate the feasibility of using a [(14)C]labeled microdose to study AAP pharmacokinetics, including metabolite disposition, in young children. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-014-0176-8) contains supplementary material, which is available to authorized users.